Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
The positron emission tomography (PET) radiotracer Pittsburgh Compound-B (PiB) binds with high affinity to beta-pleated sheet aggregates of the amyloid-beta (Abeta) peptide in vitro. The in vivo retention of PiB in brains of people with Alzheimer's disease shows a regional distribution that is very similar to distribution of Abeta deposits observed post-mortem. However, the basis for regional variations in PiB binding in vivo, and the extent to which it binds to different types of Abeta-containing plaques and tau-containing neurofibrillary tangles (NFT), has not been thoroughly investigated. The present study examined 28 clinically diagnosed and autopsy-confirmed Alzheimer's disease subjects, including one Alzheimer's disease subject who had undergone PiB-PET imaging 10 months prior to death, to evaluate region- and substrate-specific binding of the highly fluorescent PiB derivative 6-CN-PiB. These data were then correlated with region-matched Abeta plaque load and peptide levels, [(3)H]PiB binding in vitro, and in vivo PET retention levels. We found that in Alzheimer's disease brain tissue sections, the preponderance of 6-CN-PiB binding is in plaques immunoreactive to either Abeta42 or Abeta40, and to vascular Abeta deposits. 6-CN-PiB labelling was most robust in compact/cored plaques in the prefrontal and temporal cortices. While diffuse plaques, including those in caudate nucleus and presubiculum, were less prominently labelled, amorphous Abeta plaques in the cerebellum were not detectable with 6-CN-PiB. Only a small subset of NFT were 6-CN-PiB positive; these resembled extracellular 'ghost' NFT. In Alzheimer's disease brain tissue homogenates, there was a direct correlation between [(3)H]PiB binding and insoluble Abeta peptide levels. In the Alzheimer's disease subject who underwent PiB-PET prior to death, in vivo PiB retention levels correlated directly with region-matched post-mortem measures of [(3)H]PiB binding, insoluble Abeta peptide levels, 6-CN-PiB- and Abeta plaque load, but not with measures of NFT. These results demonstrate, in a typical Alzheimer's disease brain, that PiB binding is highly selective for insoluble (fibrillar) Abeta deposits, and not for neurofibrillary pathology. The strong direct correlation of in vivo PiB retention with region-matched quantitative analyses of Abeta plaques in the same subject supports the validity of PiB-PET imaging as a method for in vivo evaluation of Abeta plaque burden.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





![Fig. 6 Correlations of the in vivo PiB DVR values from the 19 VOIs (six of the 25 VOIs had <70% tissue and were not included in the analysis, see Methods section) on the PET scan with post-mortem quantifications of 6-CN-PiB (A) or Aβ (B) plaque load, neurofibrillary load (C) and [3H]PiB binding (D) in the corresponding 19 tissue cubes from the formalin fixed left hemisphere. In vivo PiB-PET retention (DVR) levels correlate directly with regional post-mortem quantitations of 6-CN-PiB (A) and 6E10 (B) plaque loads as well as in vitro PiB binding (D), but not with AT8 neurofibrillary load (C) in formalin-fixed tissue from the left hemisphere. In fresh-frozen tissue from the right hemisphere of the same Alzheimer's disease subject, there is a significant correlation of both in vitro PiB binding (E) and total insoluble Aβ (Aβ1–40 + Aβ1–42) peptide levels (F) with in vivo PiB-PET retention (DVR) levels.](https://figures.cochat.ai/paper-figures/e33db6b5b74a421cb6ab860a36a812a8/post-mortem-correlates-of-in-vivo-pib-pet-amyloid-imaging-in-a-typical-case-of-figure-6.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“in accordance with the relative resistance of this region to pathology in mouse AD models and AD patients26”
From Transcriptional signature in microglia associated with Aβ plaque phagocytosis (2021) · cites this paper as [26]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recent amyloid imaging techniques have proved an association with Alzheimer disease pathology235 and may prove useful for evaluating the independent and combined effects of vascular and Alzheimer disease brain injury on cognitive changes during normal aging in the future.”
The cited source says what the claim attributes to it.
In the citing paper
“Imaging-to-autopsy comparison studies have established that amyloid positron emission tomography (PET) is a valid in vivo surrogate for Aβ deposits (in brain parenchyma/vessel walls) [17–24].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“the [11C]-benzothiazole radiotracer, Pittsburgh Compound B (PIB), as well as other tracers, can bind to fibrillar Aβ plaques, allowing for visualization of brain amyloid in individuals during positron emission tomography (PET) (23-25).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 3×
“In this case, the final neuropathological diagnosis by CERAD criteria (Mirra et al., 1991) was ‘definite Alzheimer’s disease’, and the Braak stage (Braak and Braak, 1991b) was V/VI.”
BackgroundResultMirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496 · cited 7×
“…Alzheimer’s disease patients have 2- to 3-fold greater PiB retention on PET scans in brain areas known to have high amounts of fibrillar (i.e. Congo red and thioflavin-S labelled) Ab plaques in Alzheimer’s disease, such as frontal cortex and temporal lobe (Klunk et al., 2004; Price et al., 2005).”
BackgroundInfluentialSelf-citationGauthier, S., Reisberg, B., Zaudig, M., Petersen, R. C., Ritchie, K., Broich, K., Belleville, S., Brodaty, H., Bennett, D., Chertkow, H., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68542-5 · Cited by 3,850
Diagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499
Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
Fillenbaum, G. G., & Heyman, A. (2002) · Principles and Practice of Geriatric Psychiatry · doi:10.1002/0470846410.ch42(iii · Cited by 2,410
Simplified Reference Tissue Model for PET Receptor Studies
Lammertsma, A. A., & Hume, S. P. (1996) · NeuroImage · doi:10.1006/nimg.1996.0066 · Cited by 2,021 · cited 1×
“Logan graphical analyses (Logan et al., 1996) were performed for 35–60min (5 points) intervals using input functions derived from cerebellar tissue radioactivity to yield the DVR as the outcome measure (Lammertsma and Hume, 1996).”
MethodIwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y. (1994) · Neuron · doi:10.1016/0896-6273(94)90458-8 · Cited by 1,774 · cited 1×
“Ab42-containing plaques and Ab42 peptide levels are much more abundant in Alzheimer’s disease brain (Iwatsubo et al., 1994; Naslund et al., 2000), and therefore likely drive the correlation between PiB and total Ab peptide (Ab42 and Ab40 combined) levels as determined in our ELISA assays.”
Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data
Logan, J., Fowler, J. S., Volkow, N. D., Wang, G.-J., Ding, Y.-S., & Alexoff, D. L. (1996) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199609000-00008 · Cited by 1,514 · cited 1×
“Logan graphical analyses (Logan et al., 1996) were performed for 35–60min (5 points) intervals using input functions derived from cerebellar tissue radioactivity to yield the DVR as the outcome measure (Lammertsma and Hume, 1996).”
Method
Research works printed but not linked: 2
- Braak, 1991, Neuropathological staging of Alzheimer's disease, Acta Neuropath, 82, 239, 10.1007/BF00308809 · DOI · Paper page
- Kim, 1990, Detection and quantification of β-peptide with two monoclonal antibodies, Neurosci Res Commun, 7, 113
Cited by
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
“PiB specifically binds to fibrillar A β , and not to soluble A β or to diffuse plaques.26 35 The evidence therefore strongly supports the notion that both amyloid imaging and low CSF A β 42 are valid biomarkers of brain A β -plaque load.”
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Gorelick, P. B., Scuteri, A., Black, S. E., DeCarli, C., Greenberg, S. M., Iadecola, C., Launer, L. J., Laurent, S., Lopez, O. L., Nyenhuis, D., et al. (2011) · Stroke · doi:10.1161/str.0b013e3182299496 · Cited by 3,811
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Self-citation2018 Alzheimer's disease facts and figures
Alzheimer's Association (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.001 · Cited by 1,912
Revising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869
Self-citationA/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Feldman, H. H., Frisoni, G. B., Hampel, H., Jagust, W. J., Johnson, K. A., Knopman, D. S., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002923 · Cited by 1,864
Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance
Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002156 · Cited by 1,242
“Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1-40).”
InfluentialClinical Neurology and Epidemiology of the Major Neurodegenerative Diseases
Erkkinen, M. G., Kim, M.-O., & Geschwind, M. D. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a033118 · Cited by 1,124
“PET studies that use tracers that specifically bind amyloid (C11PiB [Klunk et al. 2004; Ikonomovic et al. 2008], F18-florbetapir [Wong et al. 2010; Clark et al. 2011, 2012], F18-flutemetamol [Vandenberghe et al. 2010; Wolk et al. 2011], and F18-florbetaben [Rowe et al. 2008]) can noninvasively…”
BackgroundJack, C. R., Lowe, V. J., Weigand, S. D., Wiste, H. J., Senjem, M. L., Knopman, D. S., Shiung, M. M., Gunter, J. L., Boeve, B. F., Kemp, B. J., et al. (2009) · Brain · doi:10.1093/brain/awp062 · Cited by 1,099
“…as 11 C Pittsburgh compound B (PIB) primarily measure brain amyloid plaque load (Klunk et al ., 2004; Rowe et al ., 2007; Drzezga et al ., 2008; Ikonomovic et al ., 2008; Leinonen et al ., 2008) but also localize in cerebral vascular amyloid (Bacskai et al ., 2007; Johnson et al ., 2007;…”
Frequent amyloid deposition without significant cognitive impairment among the elderly
Aizenstein, H. J., Nebes, R. D., Saxton, J. A., Price, J. C., Mathis, C. A., Tsopelas, N. D., Ziolko, S. K., James, J. A., Snitz, B. E., Houck, P. R., et al. (2008) · Archives of Neurology · doi:10.1001/archneur.65.11.1509 · Cited by 1,059
“cerebellum.(8,9) The aim of the present study was to characterize the relationship of amyloid deposition with cognition among elderly persons using PiB positron emission tomography (PET) imaging.”
Self-citationBiomarker Modeling of Alzheimer’s Disease
Jack, C. R., & Holtzman, D. M. (2013) · Neuron · doi:10.1016/j.neuron.2013.12.003 · Cited by 1,002
Brain Imaging in Alzheimer Disease
Johnson, K. A., Fox, N. C., Sperling, R. A., & Klunk, W. E. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006213 · Cited by 875
“…to be equivalent as screening tools for clinical trials, but the more dynamic nature of amyloid PET and the fact that amyloid tracer retention correlates directly with Ab load (Ikonomovic et al. 2008) makes this a more suitable outcome measure when the goal is to detect changes in brain Ab load.”
BackgroundInfluentialSelf-citationAPOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging
Morris, J. C., Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., & Mintun, M. A. (2010) · Annals of Neurology · doi:10.1002/ana.21843 · Cited by 830
The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives
Swerdlow, R. H., Burns, J. M., & Khan, S. M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.09.010 · Cited by 786
Reiman, E. M., Chen, K., Liu, X., Bandy, D., Yu, M., Lee, W., Ayutyanont, N., Keppler, J., Reeder, S. A., Langbaum, J. B. S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900345106 · Cited by 785
“11C-labeled Pittsburgh Compound B (PiB) is a PET radioligand that selectively binds to fibrillar aggregates of the A peptide (6, 7).”
BackgroundSelf-citationRinne, J. O., Brooks, D. J., Rossor, M. N., Fox, N. C., Bullock, R., Klunk, W. E., Mathis, C. A., Blennow, K., Barakos, J., Okello, A. A., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70043-0 · Cited by 701
Self-citation18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial
Vandenberghe, R., Van Laere, K., Ivanoiu, A., Salmon, E., Bastin, C., Triau, E., Hasselbalch, S., Law, I., Andersen, A., Korner, A., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22068 · Cited by 646
“The fraction of (11)C-PIB binding to hyperphosphorylated tau and -synuclein is negligible at the nanomolar concentrations administered for in vivo imaging.(1,3,4,6) In recent years, (11)C-PIB studies have been conducted in clinically probable AD,(2,4,5,7,8) various other types of cognitive disorders, as well as cognit…”
BackgroundFunctional Alterations in Memory Networks in Early Alzheimer’s Disease
Sperling, R. A., Dickerson, B. C., Pihlajamaki, M., Vannini, P., LaViolette, P. S., Vitolo, O. V., Hedden, T., Becker, J. A., Rentz, D. M., Selkoe, D. J., et al. (2010) · NeuroMolecular Medicine · doi:10.1007/s12017-009-8109-7 · Cited by 604
“Postmortem tissue studies have indicated that PiB binds specifically to amyloid-laden brain regions (Bacskai et al. 2007; Ikonomovic et al. 2008).”
BackgroundJohnson, K. A., Minoshima, S., Bohnen, N. I., Donohoe, K. J., Foster, N. L., Herscovitch, P., Karlawish, J. H., Rowe, C. C., Carrillo, M. C., Hartley, D. M., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.01.002 · Cited by 603
Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study
Sabri, O., Sabbagh, M. N., Seibyl, J., Barthel, H., Akatsu, H., Ouchi, Y., Senda, K., Murayama, S., Ishii, K., Takao, M., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.02.004 · Cited by 602
“Although there is growing evidence that all b-amyloid deposits add to the course of AD [25], and the National Institute on Aging - Alzheimer’s Association NIA-AA guidelines added nonneuritic b-amyloid deposition in form of modified Thal stages to the neuropathological assessment of AD [26], the binding of bamyloid ima…”
BackgroundBarthel, H., Gertz, H.-J., Dresel, S., Peters, O., Bartenstein, P., Buerger, K., Hiemeyer, F., Wittemer-Rump, S. M., Seibyl, J., Reininger, C., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70077-1 · Cited by 591
Disruption of Functional Connectivity in Clinically Normal Older Adults Harboring Amyloid Burden
Hedden, T., Van Dijk, K. R. A., Becker, J. A., Mehta, A., Sperling, R. A., Johnson, K. A., & Buckner, R. L. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3189-09.2009 · Cited by 598
Ossenkoppele, R., Pijnenburg, Y. A. L., Perry, D. C., Cohn-Sheehy, B. I., Scheltens, N. M. E., Vogel, J. W., Kramer, J. H., van der Vlies, A. E., Joie, R. L., Rosen, H. J., et al. (2015) · Brain · doi:10.1093/brain/awv191 · Cited by 548
“Amyloid PET and CSF biomarkers correlate with a neuropathological diagnosis of Alzheimer’s disease (Strozyk et al., 2003; Ikonomovic et al., 2008) and there is excellent concordance between PET and CSF (Landau et al.”
BackgroundJack, C. R., Wiste, H. J., Vemuri, P., Weigand, S. D., Senjem, M. L., Zeng, G., Bernstein, M. A., Gunter, J. L., Pankratz, V. S., Aisen, P. S., et al. (2010) · Brain · doi:10.1093/brain/awq277 · Cited by 531
“…al., 2008b; Whitwell et al., 2008), while both PET amyloid imaging (Klunk et al., 2004; Edison et al., 2007; Rowe et al., 2007; Drzezga et al., 2008; Ikonomovic et al., 2008; Leinonen et al., 2008; Frisoni et al., 2009; Tolboom et al., 2009) and decreased CSF Ab42 (Clark et al., 2003; Strozyk et…”
Functional network disruption in the degenerative dementias
Pievani, M., de Haan, W., Wu, T., Seeley, W. W., & Frisoni, G. B. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70158-2 · Cited by 481
Aβ amyloid and glucose metabolism in three variants of primary progressive aphasia
Rabinovici, G. D., Jagust, W. J., Furst, A. J., Ogar, J. M., Racine, C. A., Mormino, E. C., O'Neil, J. P., Lal, R. A., Dronkers, N. F., Miller, B. L., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21451 · Cited by 477
“Neuropsychiatric Inventory Totala 8.0 (2-23) 8.0 (0-24)b 16.0 ( 4-32 ) 0.61 a Greatest possible test scores are shown in parentheses.”
BackgroundInfluentialLandau, S. M., Breault, C., Joshi, A. D., Pontecorvo, M., Mathis, C. A., Jagust, W. J., & Mintun, M. A. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.109009 · Cited by 462
“Furthermore, autopsy studies in which individuals were scanned with PiB (4) and florbetapir (5,6) before death have provided additional evidence that both PET ligands bind to fibrillar amyloid in cortex.”
Self-citationAmyloid biomarkers in Alzheimer's disease
Blennow, K., Mattsson, N., Schöll, M., Hansson, O., & Zetterberg, H. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.03.002 · Cited by 470
Circadian rest-activity pattern changes in aging and preclinical Alzheimer disease
Musiek, E. S., Bhimasani, M., Zangrilli, M. A., Morris, J. C., Holtzman, D. M., & Ju, Y.-E. S. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.4719 · Cited by 465
“Association of Preclinical Amyloid Plaque Pathology With Circadian Dysfunction Toexamine the effect of amyloid pathologyon circadianvariables, we compared only PiB+ participants (n = 26)with PiB− participants (n = 116) because PiB is themost specific marker for fibrillar amyloidplaques.(47)After adjusting for age and…”
BackgroundThe use of PET in Alzheimer disease
Nordberg, A., Rinne, J. O., Kadir, A., & Långström, B. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.217 · Cited by 449
Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program
Beach, T. G., Adler, C. H., Sue, L. I., Serrano, G., Shill, H. A., Walker, D. G., Lue, L., Roher, A. E., Dugger, B. N., Maarouf, C., et al. (2015) · Neuropathology · doi:10.1111/neup.12189 · Cited by 460
CSF A β 42/A β 40 and A β 42/A β 38 ratios: better diagnostic markers of Alzheimer disease
Janelidze, S., Zetterberg, H., Mattsson, N., Palmqvist, S., Vanderstichele, H., Lindberg, O., van Westen, D., Stomrud, E., Minthon, L., Blennow, K., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.274 · Cited by 456
Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions
Villemagne, V. L., Doré, V., Burnham, S. C., Masters, C. L., & Rowe, C. C. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2018.9 · Cited by 441
Carter, S. F., Schöll, M., Almkvist, O., Wall, A., Engler, H., Långström, B., & Nordberg, A. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.087031 · Cited by 442
“Postmortem investigations (21,39) have shown that in vivo 11C-PIB retention is strongly correlated with the 11C-PIB binding in postmortem tissue throughout the brain.”
BackgroundMechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab
Ostrowitzki, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.1538 · Cited by 431
Villeneuve, S., Rabinovici, G. D., Cohn-Sheehy, B. I., Madison, C., Ayakta, N., Ghosh, P. M., La Joie, R., Arthur-Bentil, S. K., Vogel, J. W., Marks, S. M., et al. (2015) · Brain · doi:10.1093/brain/awv112 · Cited by 408
Brain β-amyloid load approaches a plateau
Jack, C. R., Wiste, H. J., Lesnick, T. G., Weigand, S. D., Knopman, D. S., Vemuri, P., Pankratz, V. S., Senjem, M. L., Gunter, J. L., Mielke, M. M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182840bbe · Cited by 406
Brain PET in the Diagnosis of Alzheimer’s Disease
Marcus, C., Mena, E., & Subramaniam, R. M. (2014) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000000547 · Cited by 382
“AD and 651 subjects with normal cognitive performance, concluding that 96% of the patients with clinically suspected AD had amyloid imaging positive result, with an SP of 76%.(46,54,56,60,61) The degree of cortical binding of amyloid agent in patients with AD is highly variable and does not correlate with clinical mea…”
Conceptual and Measurement Challenges in Research on Cognitive Reserve
Jones, R. N., Manly, J., Glymour, M. M., Rentz, D. M., Jefferson, A. L., & Stern, Y. (2011) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617710001748 · Cited by 363
“Consequently, a sufficient quantity of data across the range of pathology under consideration and careful data analysis are required to avoid spurious inference regarding the influence of baseline factors. identified and are not widely available (Ikonomovic et al., 2008; Rentz et al., 2010).”
BackgroundBabiloni, C., Lizio, R., Marzano, N., Capotosto, P., Soricelli, A., Triggiani, A. I., Cordone, S., Gesualdo, L., & Del Percio, C. (2016) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2015.02.008 · Cited by 359
“…(FDG-PET) mapping of temporo-parietal and precuneus hypometabolism (Jagust et al., 2007; Minoshima et al., 1997); PET-amyloid Pittsburg Compound B (PIB) is also used for the visualization of Aβ deposition in the brain (Klunk et al., 2004; Rowe et al., 2007; Ikonomovic et al., 2008).”
MethodDissecting phenotypic traits linked to human resilience to Alzheimer’s pathology
Perez-Nievas, B. G., Stein, T. D., Tai, H.-C., Dols-Icardo, O., Scotton, T. C., Barroeta-Espar, I., Fernandez-Carballo, L., de Munain, E. L., Perez, J., Marquie, M., et al. (2013) · Brain · doi:10.1093/brain/awt171 · Cited by 387
“Amyloid neuroimaging has made it possible to identify amyloid deposition in vivo (Klunk et al., 2004) and recent studies have suggested that Pittsburgh compound B binds to fibrillar amyloid-b deposits (Lockhart et al., 2007; Ikonomovic et al., 2008).”
BackgroundSelf-citationRelationship between atrophy and β‐amyloid deposition in Alzheimer disease
Chételat, G., Villemagne, V. L., Bourgeat, P., Pike, K. E., Jones, G., Ames, D., Ellis, K. A., Szoeke, C., Martins, R. N., O'Keefe, G. J., et al. (2010) · Annals of Neurology · doi:10.1002/ana.21955 · Cited by 373
“It is now possible to measure both atrophy and -amyloid load in vivo using magnetic resonance imaging (MRI) as an indirect measure of synaptic and neuronal atrophy, and the recently developed [(11)C]Pittsburgh compound B (PiB) positron emission tomography (PET) radiotracer that binds to fibrillar -amyloid plaques.(4)…”
BackgroundFleisher, A. S. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.150 · Cited by 364
“Between-group comparisons revealed increased florbetapir F 18 positivity associated with clinical severity in distribution patterns consistent with known fibrillar amyloid deposition in AD.15,16 In addition, clinical severity was distinguishable by florbetapir PET even when controlling for the effects of APOE ε4 gene…”
BackgroundInfluentialTranscriptional signature in microglia associated with Aβ plaque phagocytosis
Grubman, A., Choo, X. Y., Chew, G., Ouyang, J. F., Sun, G., Croft, N. P., Rossello, F. J., Simmons, R., Buckberry, S., Landin, D. V., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23111-1 · Cited by 357
Amyloid imaging in mild cognitive impairment subtypes
Wolk, D. A., Price, J. C., Saxton, J. A., Snitz, B. E., James, J. A., Lopez, O. L., Aizenstein, H. J., Cohen, A. D., Weissfeld, L. A., Mathis, C. A., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21598 · Cited by 339
Self-citationMormino, E. C., Smiljic, A., Hayenga, A. O., H. Onami, S., Greicius, M. D., Rabinovici, G. D., Janabi, M., Baker, S. L., V. Yen, I., Madison, C. M., et al. (2011) · Cerebral Cortex · doi:10.1093/cercor/bhr025 · Cited by 336
“PIB does not bind to diffuse plaques or soluble Ab (Ikonomovic et al. 2008), which may show more relevance than fibrillar Ab in evaluating the regional impact of this pathology on DMN FC.”
Background18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease
Fodero-Tavoletti, M. T., Okamura, N., Furumoto, S., Mulligan, R. S., Connor, A. R., McLean, C. A., Cao, D., Rigopoulos, A., Cartwright, G. A., O'Keefe, G., et al. (2011) · Brain · doi:10.1093/brain/awr038 · Cited by 328
“Recent reports indicate that the best characterized and successful imaging agent Pittsburgh Compound-B (PiB), preferentially binds to fibrillar b-amyloid contained within cored and compact plaques (Klunk et al., 2004; Maeda et al., 2007; Ikonomovic et al., 2008) and with much lower affinity to the oligomeric forms of…”
BackgroundNelissen, N., Van Laere, K., Thurfjell, L., Owenius, R., Vandenbulcke, M., Koole, M., Bormans, G., Brooks, D. J., & Vandenberghe, R. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.063305 · Cited by 330
Curtis, C., Gamez, J. E., Singh, U., Sadowsky, C. H., Villena, T., Sabbagh, M. N., Beach, T. G., Duara, R., Fleisher, A. S., Frey, K. A., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4144 · Cited by 332
“39) [0-30] 8.”
Johnson, K. A., Minoshima, S., Bohnen, N. I., Donohoe, K. J., Foster, N. L., Herscovitch, P., Karlawish, J. H., Rowe, C. C., Carrillo, M. C., Hartley, D. M., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.120618 · Cited by 329
Lehmann, M., Ghosh, P. M., Madison, C., Laforce, R., Corbetta-Rastelli, C., Weiner, M. W., Greicius, M. D., Seeley, W. W., Gorno-Tempini, M. L., Rosen, H. J., et al. (2013) · Brain · doi:10.1093/brain/aws327 · Cited by 325
“It is also conceivable that distinct clinico-anatomical features in Alzheimer's disease variants may be driven by amyloid species that are not captured by PIB, such as soluble amyloid-b or diffuse plaques (Bacskai et al., 2007; Ikonomovic et al., 2008).”
BackgroundMurray, M. E., Lowe, V. J., Graff-Radford, N. R., Liesinger, A. M., Cannon, A., Przybelski, S. A., Rawal, B., Parisi, J. E., Petersen, R. C., Kantarci, K., et al. (2015) · Brain · doi:10.1093/brain/awv050 · Cited by 324
“, 1991), both of which have fibrillar forms of amyloid that bind the fluorescent analogue of PiB or radiolabelled PiB (Lockhart et al., 2007; Ikonomovic et al., 2008).”
BackgroundInfluentialLeyton, C. E., Villemagne, V. L., Savage, S., Pike, K. E., Ballard, K. J., Piguet, O., Burrell, J. R., Rowe, C. C., & Hodges, J. R. (2011) · Brain · doi:10.1093/brain/awr216 · Cited by 313
“burden in pathologically confirmed cases (Bacskai et al., 2007; Ikonomovic et al., 2008).”
BackgroundLa Joie, R., Ayakta, N., Seeley, W. W., Borys, E., Boxer, A. L., DeCarli, C., Doré, V., Grinberg, L. T., Huang, E., Hwang, J., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.09.001 · Cited by 317
Self-citationStorandt, M., Mintun, M. A., Head, D., & Morris, J. C. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.272 · Cited by 304
Weller, R. O., Boche, D., & Nicoll, J. A. R. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0498-z · Cited by 297
“The hypothesis is now testable because of the recent ability to image amyloid plaques in vivo using PIB PET imaging [ 39 ] and it is likely that the relevant data with which to test the hypothesis will be available soon.”
BackgroundRabinovici, G. D., Furst, A. J., Alkalay, A., Racine, C. A., O’Neil, J. P., Janabi, M., Baker, S. L., Agarwal, N., Bonasera, S. J., Mormino, E. C., et al. (2010) · Brain · doi:10.1093/brain/awp326 · Cited by 280
“PIB-PET is a relatively new technique, and although early clinicopathologic studies suggest that in vivo PIB signal correlates strongly with post-mortem measures of amyloid-b (Bacskai et al., 2007; Ikonomovic et al., 2008), the limitations of PIB have not yet been fully defined.”
BackgroundRowe, C. C., & Villemagne, V. L. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.076315 · Cited by 261
“The regional retention of 11C-PiB reflects the regional density of Ab plaques, as reported at autopsy (55,56) and as measured by quantification of immunohistochemical staining of brain slices, with a higher plaque density in the frontal cortex than in the hippocampus, consistent with previous neuropathologic and 11C-P…”
ResultGrimmer, T., Riemenschneider, M., Förstl, H., Henriksen, G., Klunk, W. E., Mathis, C. A., Shiga, T., Wester, H.-J., Kurz, A., & Drzezga, A. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.01.027 · Cited by 278
“Beta amyloid [1-42] concentrations above 643 ng/L were considered as normal (7).”
BackgroundSelf-citationMultimodal imaging in Alzheimer's disease: validity and usefulness for early detection
Teipel, S., Drzezga, A., Grothe, M. J., Barthel, H., Chételat, G., Schuff, N., Skudlarski, P., Cavedo, E., Frisoni, G. B., Hoffmann, W., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00093-9 · Cited by 267
Acute and chronic traumatic encephalopathies: pathogenesis and biomarkers
DeKosky, S. T., Blennow, K., Ikonomovic, M. D., & Gandy, S. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.36 · Cited by 268
Self-citationJohnson, K. A., Sperling, R. A., Gidicsin, C. M., Carmasin, J. S., Maye, J. E., Coleman, R. E., Reiman, E. M., Sabbagh, M. N., Sadowsky, C. H., Fleisher, A. S., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.10.007 · Cited by 270
“Previous reports have indicated that the prevalence of abnormal Ab deposition rises in normal aging [4,8,15,35,43,47,54,55].”
BackgroundHead (2012) · doi:10.1001/archneurol.2011.845 · Cited by 267
Shaw, L. M., Arias, J., Blennow, K., Galasko, D., Molinuevo, J. L., Salloway, S., Schindler, S., Carrillo, M. C., Hendrix, J. A., Ross, A., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.07.220 · Cited by 266
“[67] Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al.”
BackgroundNeuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer's disease
Wang, X., Huang, W., Su, L., Xing, Y., Jessen, F., Sun, Y., Shu, N., & Han, Y. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00395-3 · Cited by 265
Morris, E., Chalkidou, A., Hammers, A., Peacock, J., Summers, J., & Keevil, S. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3228-x · Cited by 248
“The reason for the latter is that treatments intended to remove amyloid beta plaques may have modest effects on the amyloid PET signal that are not apparent by visual comparison of scans [12, 40].”
BackgroundUsing PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment
Camus, V., Payoux, P., Barré, L., Desgranges, B., Voisin, T., Tauber, C., La Joie, R., Tafani, M., Hommet, C., Chételat, G., et al. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-2021-8 · Cited by 252
“Our results also indicate that there is high uptake of florbetapir in the white matter (centrum semiovale) and the striatum region (in particular, the putamen) to a similar degree as with other (11)C- [39, 40] and (18)F-labelled compounds [17, 41, 42].”
ResultClinical syndromes associated with posterior atrophy: Early age at onset AD spectrum
Migliaccio, R., Agosta, F., Rascovsky, K., Karydas, A., Bonasera, S., Rabinovici, G. D., Miller, B. L., & Gorno-Tempini, M. L. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c0d427 · Cited by 253
Villain, N., Chételat, G., Grassiot, B., Bourgeat, P., Jones, G., Ellis, K. A., Ames, D., Martins, R. N., Eustache, F., Salvado, O., et al. (2012) · Brain · doi:10.1093/brain/aws125 · Cited by 255
“Indeed, PiB binds to fibrillar amyloid-b, found in both cored and non-cored plaques (Ikonomovic et al., 2008), while other amyloid-b tracers only bind to cored plaques (Kudo et al.”
BackgroundImaging biomarkers in neurodegeneration: current and future practices
Young, P. N. E., Estarellas, M., Coomans, E., Srikrishna, M., Beaumont, H., Maass, A., Venkataraman, A. V., Lissaman, R., Jiménez, D., Betts, M. J., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00612-7 · Cited by 225
Emerging Concepts in Alzheimer's Disease
Vinters, H. V. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020712-163927 · Cited by 235
Cohen, A. D., Price, J. C., Weissfeld, L. A., James, J., Rosario, B. L., Bi, W., Nebes, R. D., Saxton, J. A., Snitz, B. E., Aizenstein, H. A., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3669-09.2009 · Cited by 240
“The analysis of amyloid-β deposition using PiB-PET is a more recent technology (Klunk et al., 2004; Ikonomovic et al., 2008), but the role of Aβ in AD pathogenesis has led to comparisons of Aβ deposition and metabolism in AD.”
MethodSelf-citationMattsson, N., Insel, P. S., Donohue, M., Landau, S., Jagust, W. J., Shaw, L. M., Trojanowski, J. Q., Zetterberg, H., Blennow, K., & Weiner, M. W. (2015) · Brain · doi:10.1093/brain/awu367 · Cited by 237
“First, PET amyloid-b is directly related to brain fibrillar amyloid-b (Ikonomovic et al., 2008), whereas CSF amyloid-b is a marker of soluble amyloid-b and only indirectly related to fibrillar amyloid-b.”
Cerebral Microbleeds: A Review of Clinical, Genetic, and Neuroimaging Associations
Yates, P. A., Villemagne, V. L., Ellis, K. A., Desmond, P. M., Masters, C. L., & Rowe, C. C. (2014) · Frontiers in Neurology · doi:10.3389/fneur.2013.00205 · Cited by 231
“PiB can also highlight presence of β-amyloid in cerebral vessel walls, even in the absence of parenchymal plaques, both in vitro (88) and in vivo with subsequent post-mortem follow-up (89, 90).”
BackgroundToledo, J. B., Van Deerlin, V. M., Lee, E. B., Suh, E., Baek, Y., Robinson, J. L., Xie, S. X., McBride, J., Wood, E. M., Schuck, T., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.06.003 · Cited by 234
Amyloid Imaging in Aging and Dementia: Testing the Amyloid Hypothesis In Vivo
Rabinovici, G. D., & Jagust, W. J. (2009) · Behavioural Neurology · doi:10.1155/2009/609839 · Cited by 185
Zhang, X., Tian, Y., Zhang, C., Tian, X., Ross, A. W., Moir, R. D., Sun, H., Tanzi, R. E., Moore, A., & Ran, C. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1505420112 · Cited by 225
Kim, H. J., Seo, S. W., Chang, J. W., Lee, J. I., Kim, C. H., Chin, J., Choi, S. J., Kwon, H., Yun, H. J., Lee, J. M., et al. (2015) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2015.06.007 · Cited by 220
“First, PiB-PETmay not be sufficiently sensitive to detect soluble amyloid or diffuse amyloid plaques [24].”
BackgroundMethodBrain FDG PET and the Diagnosis of Dementia
Shivamurthy, V. K. N., Tahari, A. K., Marcus, C., & Subramaniam, R. M. (2015) · American Journal of Roentgenology · doi:10.2214/ajr.13.12363 · Cited by 227
“It is a derivative of thioflavin-T amyloid dye and binds with high affinity and high specificity to neuritic amyloid-β plaques [77, 78].”
BackgroundClinical Validation of 18F-AZD4694, an Amyloid-β–Specific PET Radioligand
Cselényi, Z., Jönhagen, M. E., Forsberg, A., Halldin, C., Julin, P., Schou, M., Johnström, P., Varnäs, K., Svensson, S., & Farde, L. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.094029 · Cited by 224
“The first and so-far most successful radioligand is 11C-labeled 2-[49-(methylamino) phenyl]-6-hydroxybenzothiazole (11C-PIB), which binds predominantly to amyloid-b plaques in the human brain (1).”
BackgroundBiomarkers for the Early Detection and Progression of Alzheimer's Disease
Counts, S. E., Ikonomovic, M. D., Mercado, N., Vega, I. E., & Mufson, E. J. (2017) · Neurotherapeutics · doi:10.1007/s13311-016-0481-z · Cited by 224
Lifespan brain activity, β-amyloid, and Alzheimer's disease
Jagust, W. J., & Mormino, E. C. (2011) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2011.09.004 · Cited by 221
“The most widely used PET amyloid imaging tracer is [11C]PIB (Pittsburgh compound B), a thioflavin derivative whose distribution reflects fibrillar, aggregated plaques [8,9].”
MethodBourgeat, P., Chételat, G., Villemagne, V. L., Fripp, J., Raniga, P., Pike, K., Acosta, O., Szoeke, C., Ourselin, S., Ames, D., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181c918b5 · Cited by 220
Koole, M., Lewis, D. M., Buckley, C., Nelissen, N., Vandenbulcke, M., Brooks, D. J., Vandenberghe, R., & Van Laere, K. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.060756 · Cited by 212
“11C-PIB shows a 2-fold increase in cortical signal in probable AD patients versus controls, and neuropathologic studies have confirmed that regional 11C-PIB binding in vivo correlates with levels of Ab measured after death (8).”
BackgroundAlzheimer disease: new concepts on its neurobiology and the clinical role imaging will play
Jack, C. R. (2012) · Radiology · doi:10.1148/radiol.12110433 · Cited by 211
Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer’s disease
Pereira, J. B., Janelidze, S., Ossenkoppele, R., Kvartsberg, H., Brinkmalm, A., Mattsson-Carlgren, N., Stomrud, E., Smith, R., Zetterberg, H., Blennow, K., et al. (2021) · Brain · doi:10.1093/brain/awaa395 · Cited by 203
“Thus, our study has the advantage of measuring a constellation of synaptic and axonal markers in individuals who also underwent amyloid PET and tau PET, which are thought to reflect the formation of neuritic plaques (Ikonomovic et al., 2008) and tangles (Sato et al.”
BackgroundCairns, N. J., Ikonomovic, M. D., Benzinger, T., Storandt, M., Fagan, A. M., Shah, A. R., Reinwald, L. T., Carter, D., Felton, A., Holtzman, D. M., et al. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.279 · Cited by 205
“These included quantitative assessment of radiolabeled tritium [3H] PiB binding to brain homogenates and ELISA of A 1-42 using the antibodies and procedures described in detail by Ikonomovic et al.27 REPORT OF A CASE An 85-year-old male civil servant with 12 years of education and without a family history of dementia…”
MethodInfluentialSelf-citationFleisher, A. S., Chen, K., Liu, X., Ayutyanont, N., Roontiva, A., Thiyyagura, P., Protas, H., Joshi, A. D., Sabbagh, M., Sadowsky, C. H., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.04.017 · Cited by 202
Ramanan, V. K., Risacher, S. L., Nho, K., Kim, S., Swaminathan, S., Shen, L., Foroud, T. M., Hakonarson, H., Huentelman, M. J., Aisen, P. S., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.19 · Cited by 200
Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer’s disease
Villemagne, V. L., Mulligan, R. S., Pejoska, S., Ong, K., Jones, G., O’Keefe, G., Chan, J. G., Young, K., Tochon-Danguy, H., Masters, C. L., et al. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2088-x · Cited by 190
de Souza, L. C., Lamari, F., Belliard, S., Jardel, C., Houillier, C., De Paz, R., Dubois, B., & Sarazin, M. (2011) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2010.207183 · Cited by 193
“These distinct clinical non-fluent PPAvariantswere also observed in an in vivo study(22) that used positron tomography emission with the [11C]-Pittsburgh compound B, a radioligand thatwas designed tomeasure the amount of fibrillar Ab deposits(38) and that has been confirmed by a post-mortem study in AD.(39)Our data, s…”
InfluentialChandra, A., Valkimadi, P., Pagano, G., Cousins, O., Dervenoulas, G., Politis, M., & Initiative, F. T. A. D. N. (2019) · Human Brain Mapping · doi:10.1002/hbm.24782 · Cited by 183
“PiB PET has demonstrated the ability to bind to cored and neuritic Aβ plaques, and also diffuse ones (Ikonomovic et al., 2008).”
BackgroundRowe, C. C., Pejoska, S., Mulligan, R. S., Jones, G., Chan, J. G., Svensson, S., Cselényi, Z., Masters, C. L., & Villemagne, V. L. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.114785 · Cited by 191
Tau protein and tau aggregation inhibitors
Bulic, B., Pickhardt, M., Mandelkow, E.-M., & Mandelkow, E. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.01.016 · Cited by 180
“13), was found to have an 45 fold increased affinity toward Ab (1e40) compared to ThT (Ki(PiB) ¼ 20 nM vs. Ki(ThT) ¼ 890 nM) (Ikonomovic et al., 2008; Klunk et al., 2005, 2001; Mathis et al., 2002; Mathis et al., 2007).”
Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia
Gomperts, S. N., Locascio, J. J., Rentz, D., Santarlasci, A., Marquie, M., Johnson, K. A., & Growdon, J. H. (2013) · Neurology · doi:10.1212/wnl.0b013e31827b1a07 · Cited by 182
Type 2 diabetes as a risk factor for cognitive impairment: current insights
Umegaki, H. (2014) · Clinical Interventions in Aging · doi:10.2147/cia.s48926 · Cited by 179
“41,43 By taking advantage of recent advancements in imaging, including amyloid imaging technology with PET, 84 higher field MRI with some potential for imaging small vessel diseases, 88 and the diffusion tensor imaging method, 89 it may be possible to investigate the relative contributions of…”
Age, vascular health, and Alzheimer disease biomarkers in an elderly sample
Vemuri, P., Lesnick, T. G., Przybelski, S. A., Knopman, D. S., Lowe, V. J., Graff‐Radford, J., Roberts, R. O., Mielke, M. M., Machulda, M. M., Petersen, R. C., et al. (2017) · Annals of Neurology · doi:10.1002/ana.25071 · Cited by 182
PET amyloid-beta imaging in preclinical Alzheimer's disease
Vlassenko, A. G., Benzinger, T. L. S., & Morris, J. C. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.11.005 · Cited by 174
Metadata
- Authors
- Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., Debnath, M. L., Hope, C. E., Isanski, B. A., Hamilton, R. L., & DeKosky, S. T.
- Affiliations
- University of Pittsburgh (US)
- Corresponding author
- DeKosky, Steven T.
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-03-12
- Volume
- 131
- Issue
- 6
- Pages
- 1630-1645
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC2408940
- OpenAlex
- W2156981442
- Cited by
- 933
- References
- 66
- Citations by year
- 2026: 16 · 2025: 24 · 2024: 29 · 2023: 25 · 2022: 33 · 2021: 42 · 2020: 44 · 2019: 56 · 2018: 51 · 2017: 46 · 2016: 58 · 2015: 57 · 2014: 82 · 2013: 81 · 2012: 79
- FWCI
- 47.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Brain (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion, public-domain)
- Funders
- U.S. Department of Energy (FG02-03ER63590, DE-FD02-03 ER63590, ER63590, DE-FD02-03)
- Alzheimer's Association (AG14449, TLL-01-3381)
- University of Pittsburgh (AG05133)
- National Institute for Health and Care Research
- National Institutes of Health (AG05133, AG025204, AG14449, AG025516)
- National Institute on Aging (AG 05-133, R01AG018402, P01AG025204, RF1AG025516, P50AG005133, P01AG014449, R01AG020226, AG025516, K02AG001039, P01 AG14449, P50-AG-05133, R37AG025516, R01AG025516)
- National Institute of Mental Health (R01MH070729, K01MH001976)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- Alzheimer's disease, amyloid plaques, Pittsburgh compound B, neurofibrillary tangles, tau protein, postmortem brain, amyloid-beta 42, Aβ40, vascular amyloid deposits, prefrontal cortex, temporal cortex, cerebellum
- MeSH terms
- Alzheimer Disease, Aniline Compounds, Autopsy, Brain, Carbon Radioisotopes, Enzyme-Linked Immunosorbent Assay, Female, Humans, Image Interpretation, Computer-Assisted, Immunohistochemistry, Magnetic Resonance Imaging, Middle Aged, Thiazoles, Reproducibility of Results, Amyloid beta-Peptides, Neurofibrillary Tangles, tau Proteins, Positron-Emission Tomography, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.